Study Details
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Subjects with Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy
Clinicaltrials.gov ID
Astellas Study ID
7465-CL-1104
EudraCT ID
N/A
Condition
Bladder Cancer
Phase
Phase 2
Age
18 Years - N/A
Sex
Female & Male
Product
enfortumab vedotin
Type
Interventional
Trial Dates
Jul 2021 - Jan 2024
Masking
None (Open Label)
Enrollment number
40
A Single-arm, Open-label, Multi-center Phase 2 Study of Enfortumab Vedotin (ASG-22CE) in Chinese Subjects with Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy (EV-203)
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Subjects with Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site CN86001
Beijing, China
Site CN86006
Hangzhou, China
Site CN86003
Wuhan, China
Site CN86007
Nanjing, China
Site CN86002
Guangzhou, China
Site CN86009
Changsha, China
Site CN86011
Shenyang, China
Site CN86004
Shanghai, China